Beyang Therapeutics has raised nearly $30 million in an oversubscribed Series A financing round to advance its AI-powered drug discovery platform and clinical pipeline.
Legend Capital and Shanghai Healthcare Capital co-led the financing, with participation from China Medical System Holdings, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, and Harbor & Canton Capital. Existing investors Root Venture Partners and YuanBio Venture Capital also participated.
Beyang plans to use the proceeds to accelerate development of its ExCEED AI and molecular design platform, advance clinical and preclinical drug candidates, and expand its international R&D and business development teams.
Founded in 2021, Beyang developed ExCEED to combine proprietary databases with AI and computational simulation across molecular design, druggability optimization, and biological evaluation.
The platform ranked eighth among more than 350 participants in the OpenADMET blind prediction challenge. Beyang said ExCEED is designed to create novel molecular scaffolds rather than simply produce variations on existing structures.
One of the company’s lead programs, BT01001, is a small-molecule eye drop being developed for retinal diseases. The program has completed Phase I single ascending dose and multiple ascending dose studies in healthy subjects and is progressing toward first-in-patient trials.
Beyang is also developing BT01002, a second-generation Menin inhibitor for KMT2A-rearranged or NPM1-mutated acute leukemia. The company designed the candidate to overcome resistance mechanisms associated with first-generation Menin inhibitors, and the program is undergoing IND-enabling studies.
Beyang’s core team includes scientists with experience at companies including Pfizer, Merck, and Hengrui. Team members have participated in the development of three globally launched small-molecule drugs and helped advance more than 10 projects into clinical trials.
“We are grateful for the strong recognition from our Series A investors. The oversubscribed financing validates the value of our ExCEED platform and our differentiated pipeline. As our platform continues to deliver Best-in-Class potential, we are not only accelerating our proprietary pipeline but also actively seeking external collaborations to deliver high-value innovative drugs to patients and partners worldwide.”
Qiyue Hu, Founder of Beyang Therapeutics
“We observe that AI Drug Discovery (AIDD) is entering a 2.0 era characterized by vertical integration. Beyang’s team combines deep industry experience with computational expertise, establishing a distinct moat with the ExCEED platform. The platform’s ability to cover the full value chain, from de novo scaffold discovery to biological optimization, has been verified by experimental data, proving its capacity to continuously incubate high-potential candidates.”
Fei Qi, Executive Director at Legend Capital
“Beyang has generated highly differentiated molecules across multiple disease areas. We are particularly impressed by their next-generation Menin inhibitor, which addresses resistance issues through novel scaffold design, and their ophthalmic delivery platform that overcomes the limitations of invasive administration. We look forward to seeing Beyang leverage its platform strength to produce assets with strong global competitiveness.”
Qiushan Guo, President of Shanghai Healthcare Capital
